Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066363
Filing Date
2025-05-08
Accepted
2025-05-08 07:04:46
Documents
59
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q amlx-20250331.htm   iXBRL 10-Q 2264308
2 EX-10.1 amlx-ex10_1.htm EX-10.1 31372
3 EX-31.1 amlx-ex31_1.htm EX-31.1 17472
4 EX-31.2 amlx-ex31_2.htm EX-31.2 17464
5 EX-31.3 amlx-ex31_3.htm EX-31.3 17464
6 EX-32.1 amlx-ex32_1.htm EX-32.1 9523
7 EX-32.2 amlx-ex32_2.htm EX-32.2 9521
8 EX-32.3 amlx-ex32_3.htm EX-32.3 9520
  Complete submission text file 0000950170-25-066363.txt   7356561

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20250331.xsd EX-101.SCH 986252
61 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20250331_htm.xml XML 1018489
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41199 | Film No.: 25923809
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)